Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

NCT05826483 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Malignant Tumor of Lung
Poor Performance Status

Interventions

DRUG: Almonertinib

Sponsor

Guangzhou Institute of Respiratory Disease